Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo‐controlled crossover study
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Diabet. Med. 29, e184–e190 (2012) Aims Adding aldosterone receptor blockade to standard renoprotective treatment may provide additional renoprotection in patients with overt nephropathy. We expected an impact of spironolactone in early diabetic nephropathy, and for this hypothesis we studied the effect on markers of glomerular and tubular damage in patients with Type 1 diabetes and persistent microalbuminuria. Methods A double‐blind, randomized, placebo‐controlled crossover study in 21 patients with Type 1 diabetes and microalbuminuria using spironolactone 25 mg or placebo once daily, for 60 days added to standard antihypertensive treatment. After each treatment period, the primary endpoint were evaluated: urinary(u)‐albumin excretion/24 hour(h) and secondary endpoints; 24 h blood pressure, glomerular filtration rate (GFR) and markers of tubular damage: urinary liver‐type fatty‐acid binding protein (LFABP), neutrophil gelatinase associated lipocalin (NGAL) and kidney injury molecule 1 (KIM1). Results All patients completed the study. During spironolactone treatment, urinary albumin excretion rate was reduced by 60% (range 21–80%), from 90 mg/24 h to 35 mg/24 h (P = 0.01). Blood pressure (24 h) did not change during spironolactone treatment (P > 0.2 for all comparisons). The GFR (SD) decreased from 78 (6) mL/min/1.73 m 2 to 72 (6) mL/min/1.73 m 2 (P = 0.003). Urinary liver‐type fatty‐acid binding protein, neutrophil gelatinase‐associated lipocalin and kidney injury molecule 1 did not change during treatment (P > 0.3 for all comparisons). Treatment was well‐tolerated, but two patients had severe hyperkalaemia (plasma potassium = 5.7 mmol/l), which was sufficiently treated with diuretics and dietary intervention. Conclusions Spironolactone treatment in addition to standard renoprotective treatment lowers urinary albumin excretion in microalbuminuric patients with Type 1 diabetes, and thus may offer additional renoprotection independent of blood pressure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cowland, J. B., Sørensen, O. E., Sehested, M., & Borregaard, N. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.12.6630 · Cited by 354
Cited by
Muñoz-Durango, N., Fuentes, C., Castillo, A., González-Gómez, L., Vecchiola, A., Fardella, C., & Kalergis, A. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17070797 · Cited by 282
Currie, G., Taylor, A. H. M., Fujita, T., Ohtsu, H., Lindhardt, M., Rossing, P., Boesby, L., Edwards, N. C., Ferro, C. J., Townend, J. N., et al. (2016) · BMC Nephrology · doi:10.1186/s12882-016-0337-0 · Cited by 214
Self-citationAldosterone antagonists for preventing the progression of chronic kidney disease
Bolignano, D., Palmer, S. C., Navaneethan, S. D., & Strippoli, G. F. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007004.pub3 · Cited by 189
Chung, E. Y., Ruospo, M., Natale, P., Bolignano, D., Navaneethan, S. D., Palmer, S. C., & Strippoli, G. F. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007004.pub4 · Cited by 157
Diuretics for Hypertension: A Review and Update
Roush, G. C., & Sica, D. A. (2016) · American Journal of Hypertension · doi:10.1093/ajh/hpw030 · Cited by 142
Metadata
- Authors
- Nielsen, S. E., Persson, F., Frandsen, E., Sugaya, T., Hess, G., Zdunek, D., Shjoedt, K. J., Parving, H., & Rossing, P.
- Venue
- Diabetic Medicine
- Publisher
- Wiley
- Published
- 2012-07-15
- Volume
- 29
- Issue
- 8
- Pages
- e184-90
- ISSN
- 0742-3071 (ISSN-L)
- 1464-5491
- OpenAlex
- W1550649928
- Cited by
- 86
- References
- 1
- FWCI
- 7.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.